The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals.
In this application, researchers propose to utilize novel synthetic chemistry to develop a series of aliphatic tenofovir prodrugs designed to greatly enhance cellular uptake and to provide prolonged intracellular exposure to molecules with potent antiviral activity. They will further extend systemic exposure to these compounds by delivering them in slow-release nanoparticle formulations. They believe that with this “dual-modulation” of drug presentation we will provide systemic exposure to therapeutic concentrations of highly active antiviral compounds for periods of at least four weeks following intramuscular injection.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention.